Get the Stockscreener App
3.98
1.00%
-0.04
After Hours:
3.98
Oncternal Therapeutics Inc stock is traded at $3.98, with a volume of 10,560.
It is down -1.00% in the last 24 hours and down -30.78% over the past month.
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.
See More
Previous Close:
$4.02
Open:
$4.0494
24h Volume:
10,560
Relative Volume:
1.26
Market Cap:
$11.78M
Revenue:
-
Net Income/Loss:
$-39.48M
P/E Ratio:
-5.2368
EPS:
-0.76
Net Cash Flow:
$-32.16M
1W Performance:
-3.18%
1M Performance:
-30.78%
6M Performance:
-58.32%
1Y Performance:
-31.99%
1-Day Range:
$3.87
$4.18
1-Week Range:
$3.87
$4.4599
52-Week Range:
$3.2528
$13.14
Oncternal Therapeutics Inc Stock (ONCT) Company Profile
Name
Oncternal Therapeutics Inc
Sector
Industry
Phone
(858) 434-1113
Address
12230 EL CAMINO REAL, SAN DIEGO, CA
Oncternal Therapeutics Inc Stock (ONCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-21 | Initiated | Oppenheimer | Outperform |
| Feb-23-21 | Initiated | Northland Capital | Outperform |
Oncternal Therapeutics Inc Stock (ONCT) Latest News
Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com - Defense World
Oncternal Therapeutics (NASDAQ:ONCT) Research Coverage Started at StockNews.com - Defense World
ONCT (Oncternal Therapeutics) Financial Strength : 8 (As of Jun. 2024) - GuruFocus.com
Oncternal Therapeutics (NASDAQ:ONCT) PT Lowered to $18.00 at HC Wainwright - Defense World
Oncternal Therapeutics Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript - Seeking Alpha
Oncternal Therapeutics: Q2 Earnings Snapshot - CTPost
Oncternal Therapeutics: Q2 Earnings Snapshot - Houston Chronicle
Oncternal Therapeutics: Q2 Earnings Snapshot - New Haven Register
Oncternal Therapeutics: Q2 Earnings Snapshot - CT Insider
ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q2 2024 - InvestorPlace
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates - MSN
Oncternal Therapeutics: Q2 Earnings Snapshot - San Francisco Chronicle
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results - BioSpace
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Oncternal Therapeutics: Q2 Earnings Snapshot - Danbury News Times
Oncternal Therapeutics: Q2 Earnings Snapshot - The Bakersfield Californian
Oncternal Therapeutics (NASDAQ:ONCT) Stock, Analyst Ratings, Price Targets, Forecasts - Benzinga
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results - GlobeNewswire
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results - StockTitan
Oncternal Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News
Oncternal Therapeutics (ONCT) Scheduled to Post Quarterly Earnings on Thursday - Defense World
Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by StockNews.com - Defense World
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results - GlobeNewswire
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results - StockTitan
HC Wainwright Reiterates Buy Rating for Oncternal Therapeutics (NASDAQ:ONCT) - Defense World
When the Price of (ONCT) Talks, People Listen - Stock Traders Daily
Oncternal Announces Enrollment Completed and Dosing - GlobeNewswire
Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer - StockTitan
StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT) - American Banking and Market News
Oncternal Therapeutics to Present in JonesTrading Healthcare Summit - StockTitan
Oncternal Therapeutics to Present in JonesTrading Healthcare Summit - GlobeNewswire
(ONCT) Technical Pivots with Risk Controls - Stock Traders Daily
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference - Quantisnow
StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT) - Defense World
Oncternal (ONCT) Down on Restructuring Plan to Extend Runway - Yahoo Singapore News
StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT) - Defense World
We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation - Simply Wall St
Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.com - Defense World
Oncternal Therapeutics (NASDAQ:ONCT) Receives “Buy” Rating from HC Wainwright - Defense World
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT ... - GlobeNewswire
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer - Yahoo Finance
(ONCT) Technical Data - Stock Traders Daily
Deal Watch: Oncternal Goes Public Via Reverse Merger With GTx - Scrip
B-cell Lymphoma Pipeline Assessment, 2024 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical ... - openPR
How the (ONCT) price action is used to our Advantage - Stock Traders Daily
Oncternal Therapeutics, Inc. to Post Q2 2024 Earnings of ($3.15) Per Share, HC Wainwright Forecasts (NASDAQ:ONCT) - Defense World
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) to Post Q1 2025 Earnings of ($2.42) Per Share, HC Wainwright Forecasts - Defense World
Oncternal Therapeutics (NASDAQ:ONCT) Price Target Cut to $19.00 - Defense World
Implied Volatility Surging for Oncternal Therapeutics (ONCT) Stock Options - Yahoo News UK
Oncternal Therapeutics (ONCT) Stock Forecast and Price Target 2024 - MarketBeat
Oncternal Therapeutics Inc Stock (ONCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Oncternal Therapeutics Inc Stock (ONCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wills Robert James | Director |
Mar 28 '24 |
Buy |
8.48 |
6,914 |
58,602 |
6,914 |
| HALE DAVID F | Director |
Feb 23 '24 |
Buy |
9.04 |
714 |
6,455 |
714 |
| HALE DAVID F | Director |
Feb 23 '24 |
Buy |
9.04 |
266 |
2,405 |
29,673 |
| Wills Robert James | Director |
Feb 23 '24 |
Sale |
9.04 |
980 |
8,859 |
0 |
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):